Retinal prosthesis improves visual performance of spatial motor tasks

Article

Artificial vision provided by the Argus II retinal prosthesis strengthens vision in spatial motor tasks, according to findings published in the British Journal of Ophthalmology.

Artificial vision provided by the Argus II retinal prosthesis strengthens vision in spatial motor tasks, according to findings published in the British Journal of Ophthalmology.

A study led by Dr Ashish K. Ahuja, Sight Medical Products, Sylmar, California, USA, involved 27 participants implanted with the Argus II retinal prosthesis. A 19 inch touch screen was used to display high-contrast square stimuli. The square appeared at random locations on the screen and participants were told to touch the square when it was present and then again when it disappeared. The coordinates of the square's centre were recorded.

Of the 27 eyes examined, 26 demonstrated a significant improvement in accuracy and 25 eyes demonstrated significant improvement in repeatability of results. In the group, 4 subjects showed a significant improvement in both repeatability and accuracy.

Argus II retinal prosthesis is successful in significantly improving performance in spatial motor-tasks.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.